Arcus Biosciences/RCUS

$16.58

-4.1%
-
1D1W1MYTD1YMAX

About Arcus Biosciences

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Ticker

RCUS

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Terry Rosen

Employees

577

Headquarters

Hayward, United States

RCUS Metrics

BasicAdvanced
$1.52B
Market cap
-
P/E ratio
-$4.15
EPS
0.87
Beta
-
Dividend rate
$1.52B
0.8726
$25.47
$12.95
846.42K
4.516
-25.16%
-54.87%
-29.76%
12.993
2.734
3.29
4.46%
-11.88%
14.71%

What the Analysts think about RCUS

Analyst Ratings

Majority rating from 12 analysts.
Buy

Price Targets

Average projection from 10 analysts.
136.43% upside
High $70.00
Low $24.00
$16.58
Current price
$39.20
Average price target

RCUS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-261.29% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$31M
-3.13%
Net income
$-81M
14.08%
Profit margin
-261.29%
17.77%

RCUS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 5.46%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.09
-$1.04
-$0.94
-$1.08
-
Expected
-$1.16
-$1.10
-$1.13
-$1.02
-$0.94
Surprise
-6.3%
-5.33%
-16.72%
5.46%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Arcus Biosciences stock?

Arcus Biosciences (RCUS) has a market cap of $1.52B as of April 13, 2024.

What is the P/E ratio for Arcus Biosciences stock?

The price to earnings (P/E) ratio for Arcus Biosciences (RCUS) stock is 0 as of April 13, 2024.

Does Arcus Biosciences stock pay dividends?

No, Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Arcus Biosciences dividend payment date?

Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders.

What is the beta indicator for Arcus Biosciences?

Arcus Biosciences (RCUS) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Arcus Biosciences stock price target?

The target price for Arcus Biosciences (RCUS) stock is $39.2, which is 136.43% above the current price of $16.58. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Arcus Biosciences stock

Buy or sell Arcus Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing